A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

(2019) Bixia Tang et al.   Journal of Hematology & Oncology

Toripalimab: First Global Approval

(2019) Susan J. Keam   DRUGS

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors

(2019) Maddalena Centanni et al.   CLINICAL PHARMACOKINETICS

A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors

(2019) Yuxiang Ma et al.   ONCOLOGIST

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

(2019) F Wang et al.   ANNALS OF ONCOLOGY

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)

(2019) Lu Si et al.   Translational Oncology

Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer

(2019) Tong Wu et al.   Cancer Communications

Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?

(2019) Rui-Mei Feng et al.   Cancer Communications

Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells

(2019) Jean-François Rossi et al.   Cancer Communications

The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review

(2019) Luca Mazzarella et al.   EUROPEAN JOURNAL OF CANCER

The immune landscape of esophageal cancer

(2019) Tu-Xiong Huang et al.   Cancer Communications

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

(2018) Roberta Zappasodi et al.   CANCER CELL

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

(2018) Charles S. Fuchs et al.   JAMA Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Roles of the immune system in cancer: from tumor initiation to metastatic progression

(2018) Hugo Gonzalez et al.   GENES & DEVELOPMENT

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

(2017) Leisha A. Emens et al.   EUROPEAN JOURNAL OF CANCER

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Yoon-Koo Kang et al.   LANCET

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

(2016) Toshio Shimizu et al.   INVESTIGATIONAL NEW DRUGS

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors

(2016) Noboru Yamamoto et al.   INVESTIGATIONAL NEW DRUGS

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

(2016) Kei Muro et al.   LANCET ONCOLOGY

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

(2015) A. Patnaik et al.   CLINICAL CANCER RESEARCH

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS